Imdur (Isosorbide 5 Mononitrate)

Isosorbide 5‑mononitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide relaxes vascular smooth muscle, leading to dilation of arteries and veins, which lowers cardiac preload and afterload and decreases the heart’s oxygen demand.

The specific dose and dosing schedule of Imdur are determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for isosorbide 5‑mononitrate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Imdur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imdur belongs to the nitrate class, which primarily provides vasodilation. Compared with beta‑blockers or calcium‑channel blockers, nitrates act directly on vascular smooth muscle and are often used when other agents are insufficient or contraindicated. Choice of therapy depends on patient-specific factors and physician judgment.

Imdur tablets should be stored at ambient temperature, below 25 °C, in the original container. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Imdur is taken orally as an extended‑release tablet. It is usually swallowed whole with water, and the dosing interval is set by the prescriber, often once daily. Patients should not crush, chew, or split the tablet, as this can alter drug release.

Serious risks include severe hypotension, syncope, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, a sudden drop in blood pressure, or signs of a severe allergic response.

Imdur should be avoided in patients with known hypersensitivity to isosorbide 5‑mononitrate or other nitrates, those who have taken phosphodiesterase‑5 inhibitors within 24 hours, and individuals with severe hypotension or certain cardiovascular conditions where vasodilation is contraindicated.